bluebird bio (NASDAQ:BLUE) had its price target boosted by equities researchers at BMO Capital Markets to $194.00 in a report issued on Friday, February 22nd, The Fly reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. BMO Capital Markets’ price objective points to a potential upside of 26.32% from the stock’s current price.
Other research analysts have also recently issued research reports about the company. Piper Jaffray Companies restated a “buy” rating on shares of bluebird bio in a research report on Sunday, November 4th. Maxim Group restated a “hold” rating on shares of bluebird bio in a research report on Monday, December 3rd. Cantor Fitzgerald restated a “neutral” rating and issued a $122.00 price target (down previously from $134.00) on shares of bluebird bio in a research report on Friday, February 22nd. ValuEngine cut bluebird bio from a “buy” rating to a “hold” rating in a research report on Friday, February 22nd. Finally, Oppenheimer restated a “hold” rating on shares of bluebird bio in a research report on Friday, November 2nd. One research analyst has rated the stock with a sell rating, nine have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $168.12.
BLUE stock traded down $2.52 during trading hours on Friday, hitting $153.58. 258,391 shares of the stock were exchanged, compared to its average volume of 559,355. The stock has a market capitalization of $8.58 billion, a price-to-earnings ratio of -14.38 and a beta of 2.64. bluebird bio has a 12 month low of $87.49 and a 12 month high of $199.70.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Thursday, February 21st. The biotechnology company reported ($2.72) earnings per share for the quarter, topping the consensus estimate of ($2.83) by $0.11. The firm had revenue of $19.20 million for the quarter, compared to analysts’ expectations of $9.06 million. bluebird bio had a negative return on equity of 32.15% and a negative net margin of 1,018.02%. The company’s quarterly revenue was up 357.1% compared to the same quarter last year. During the same quarter last year, the business earned ($2.52) EPS. Equities research analysts expect that bluebird bio will post -11.67 earnings per share for the current fiscal year.
In other news, insider Jeffrey T. Walsh sold 1,500 shares of bluebird bio stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $139.80, for a total transaction of $209,700.00. Following the sale, the insider now directly owns 42,421 shares of the company’s stock, valued at $5,930,455.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Davidson sold 4,910 shares of bluebird bio stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $155.77, for a total value of $764,830.70. Following the sale, the insider now directly owns 36,526 shares in the company, valued at $5,689,655.02. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,438 shares of company stock worth $5,486,744. Company insiders own 3.00% of the company’s stock.
Several institutional investors have recently bought and sold shares of BLUE. Capital International Investors lifted its stake in shares of bluebird bio by 188.6% in the third quarter. Capital International Investors now owns 3,260,636 shares of the biotechnology company’s stock worth $476,053,000 after acquiring an additional 2,130,927 shares during the period. Capital World Investors lifted its stake in shares of bluebird bio by 37.4% in the third quarter. Capital World Investors now owns 3,425,687 shares of the biotechnology company’s stock worth $500,150,000 after acquiring an additional 931,932 shares during the period. FMR LLC lifted its stake in shares of bluebird bio by 8.1% in the third quarter. FMR LLC now owns 8,123,687 shares of the biotechnology company’s stock worth $1,186,058,000 after acquiring an additional 605,797 shares during the period. Capital Research Global Investors lifted its stake in shares of bluebird bio by 8.1% in the third quarter. Capital Research Global Investors now owns 6,634,317 shares of the biotechnology company’s stock worth $968,610,000 after acquiring an additional 494,787 shares during the period. Finally, Norges Bank acquired a new position in shares of bluebird bio in the fourth quarter worth approximately $43,816,000.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Featured Article: Consumer Price Index (CPI)
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.